Imagine a world where cows are naturally resistant to devastating diseases like avian flu. Sounds like science fiction? Think again. Dr. Bonnie Mallard, a pioneering researcher at the University of Guelph, has developed a groundbreaking technology that’s turning this vision into reality. Her High Immune Response (HIR™) technology is revolutionizing animal health, and it’s already making waves in the fight against avian flu. But here’s where it gets controversial: could this technology render traditional culling practices obsolete? Let’s dive in.
For over 35 years, Dr. Mallard has dedicated her career to improving animal health, and her work has paid off in spades. Her award-winning HIR™ technology identifies animals with naturally strong immune systems, allowing farmers to breed healthier herds over generations. The idea struck her during her undergraduate studies when she observed how genetic defects in the immune system could lead to inherited disorders. If bad genetics can cause harm, she reasoned, why can’t good genetics confer protection? This simple yet profound insight has since transformed the way we approach animal breeding.
Here’s how it works: using special antigen test kits, animals are screened for their immune response. Those with the strongest reactions are labeled high-immune responders and are selectively bred to improve the overall health of the herd. Licensed to Semex, this technology has already produced Immunity+® semen, resulting in offspring that are nothing short of remarkable. These animals are:
- 50% less likely to develop infectious diseases
- Less reliant on medications and antibiotics
- Faster-growing and longer-living, saving farmers hundreds of dollars per animal annually
- Producers of higher-quality colostrum, rich in protective antibodies
- More responsive to vaccines
With millions in revenue generated, HIR™ is one of the University of Guelph’s most profitable patents. But its impact doesn’t stop there. And this is the part most people miss: HIR™ is now proving to be a game-changer in the fight against avian flu.
In 2024, avian flu jumped from poultry to dairy cows in the U.S., sparking fears of catastrophic economic losses. However, Dr. Mallard noticed something intriguing: cows bred with Immunity+® genetics were faring surprisingly well despite exposure to the H5N1 virus. This observation led to a landmark study published in the Journal of Dairy Science Communications, where over 15,000 cows from six dairy herds with confirmed avian flu outbreaks were assessed. The results were striking: cows with high Immunity+® breeding values were 24% less likely to require treatment than those with low values, demonstrating a clear link to natural resistance.
Moreover, while avian flu typically disrupts milk production, costing farmers an average of $504 USD per affected cow, Immunity+® cows experienced significantly fewer milk losses. This raises a thought-provoking question: Could HIR™ technology make culling infected animals a thing of the past? Dr. Mallard believes so, arguing that building natural resistance is a more sustainable approach than mass culling, as seen in the controversial B.C. ostrich case.
But here’s the kicker: even though this strain of avian flu hasn’t yet reached Canadian cows, Dr. Mallard warns that borders won’t stop it. ‘When this or other viruses come, animals bred for better health genetics will be better prepared,’ she asserts. In other words, while vaccines are developed, HIR™ is creating naturally resistant animals—a two-pronged approach to disease management.
The technology’s potential doesn’t stop at cows. New research is exploring its application to companion animals, sheep, turkeys, and even beef cattle. For instance, beef cattle transported over long distances often fall ill with diseases like shipping fever pneumonia. Dr. Mallard is collaborating with the Canadian Angus Association and Semex to identify which animals are more resilient and why, paving the way for healthier herds.
This groundbreaking work has earned Dr. Mallard some of Canada’s highest research honors, including the Governor General’s Award for Innovation and the NSERC Synergy Prize. She credits the University of Guelph’s Research Innovation Office for fostering the industry connections needed to bring her technology to market. ‘For a university professor, having a good business partner is crucial,’ she says, praising Semex for their role in her success.
Her journey also highlights the power of mentorship. As a student, Dr. Mallard’s master’s supervisor, Dr. Ted Burnside, introduced her to Semex’s CEO, Dr. Moe Freeman. That meeting led to immediate funding for her research—a moment she now calls ‘the speed of trust.’
Funded by the Ontario Agri-Food Innovation Alliance, Ontario Genomics, NSERC, and industry partners like Semex and Hendrix Genetics, this research is a testament to the synergy between academia and industry. But as we marvel at its achievements, we’re left with a question: Is HIR™ the future of disease prevention, or is there still a place for traditional methods like culling? What do you think? Share your thoughts in the comments below—let’s spark a conversation!
